The immunocheckpoints in modern oncology: the next 15 years
- 10 June 2015
- journal article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 15 (7) , 917-921
Abstract
The notion that the immune system can act as a key factor in controlling cancer cell proliferation and thus its stimulation may be an important resource for cancer therapy has long been known. Tumors can elude the immune system by deploying proteins that shut down the immune response by binding to specific surface receptors on immune cells. Several promising strategies have been designed to overcome cancer cells' ability to suppress the immune surveillance. Immune checkpoint molecules that block cytotoxic T-lymphocyte associated antigen-4 (ipilimumab) or the programmed death-1/programmed death-ligand 1 axis (i.e., nivolumab and pembrolizumab) promote antitumor immunity, reactivating T-cell proliferation and activity. This efficient strategy currently represents one of the major oncological breakthroughs, with impressive clinically durable responses observed in cancer patients, particularly in melanoma, renal cell carcinoma, NSCLC and more recently in bladder cancer patients. Fifteen years ago, we replaced the IL-2 and INF-α for molecular targeted therapies. Today, we believe that immune therapy will represent the future, perhaps as part of a combination of different therapeutic strategies that act synergistically in each tumor and individual patient.Keywords
This publication has 27 references indexed in Scilit:
- Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinomaCancer Immunology, Immunotherapy, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancerAnnals of Oncology, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Combining immunotherapy and targeted therapies in cancer treatmentNature Reviews Cancer, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational ResearchClinical Cancer Research, 2009
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948